AI
Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST
AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk
Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!
Read
Commented by Armin Schulz on October 17th, 2025 | 07:05 CEST
Three stocks, one trend: Jump on the momentum bandwagon with Almonty Industries, AMD, and ASML
The stock market often rewards those who recognize a trend before it becomes mainstream. This is not about short-term speculation, but about identifying companies with strong fundamental tailwinds that can drive prices higher over the long term. This momentum is fueled by structural factors: global technology shifts, geopolitical realignments, and the reorganization of critical supply chains. There is a reason why the saying goes: Go with the flow! Almonty Industries, AMD, and ASML each embody these powerful forces and currently have strong momentum on their side. Let's take a closer look.
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read
Commented by Nico Popp on October 16th, 2025 | 07:00 CEST
Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech
Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.
Read
Commented by Fabian Lorenz on October 15th, 2025 | 08:35 CEST
BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!
The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?
Read
Commented by André Will-Laudien on October 13th, 2025 | 07:15 CEST
Trump tariffs 3.0 for China and the Bitcoin crash: Major movements at Strategy, Metaplanet, Coinbase, Nakiki, and D-Wave
With Donald Trump's announcement of a new 100% tariff measure against China on Friday afternoon, previously strong performers in the crypto sector came under significant pressure. The protagonists, Strategy, Coinbase, and Metaplanet, were hit with daily losses of between 3 and 10%. D-Wave, which had gained over 50% in the last 6 weeks, is also starting to feel the squeeze. Nakiki shares, on the other hand, reacted with price gains. The German Bitcoin stock can be pleased that its coin purchase program doesn't start until November - this could offer attractive buying opportunities, with the timing looking ideal. However, it remains to be seen whether this move will trigger a broader correction accompanied by rising volatility. Meanwhile, precious metals have recently been moving in only one direction: up! Could the rally now make an abrupt return?
Read
Commented by André Will-Laudien on October 10th, 2025 | 07:10 CEST
The AI tech high-flyers! Up to 3,500% dream returns with D-Wave Quantum, Power Metallic, Nvidia and AMD
Hard to believe, but unfortunately true! Without a single setback, share prices in the AI, high-tech, and strategic metals sectors have been rising unabated for months now. This has led to dream returns, some of which are in the triple digits. The curtain call for this party seems a long way off, while underinvested investors are sitting on billions in idle cash. There is no conclusive advice for such a situation. Fundamental analysts have been sounding the alarm for months, noting that the well-known Shiller P/E ratio, at over 42, has long since broken through the band of irrational exaggeration. But who cares? Here is a selection of stocks that face daily demand, forcing constant appreciation. Of course, as with any party, it only ends when the last guest turns off the lights.
Read
Commented by Armin Schulz on October 9th, 2025 | 07:40 CEST
AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec
The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.
Read
Commented by Carsten Mainitz on October 7th, 2025 | 07:45 CEST
Aspermont, Palantir, RENK – AI sets the pace. Where is the next run?
International stock markets are booming. The Dow Jones recently surpassed 47,000 points, seemingly unaffected by the US government shutdown. The topic of artificial intelligence (AI) continues to be the focus of investor interest, and recent company announcements are causing a stir. Japanese electronics giant Hitachi and ChatGPT provider OpenAI are partnering to build AI infrastructure and global data centers. Meanwhile, Fujitsu and leading AI chip manufacturer Nvidia are expanding their collaboration and plan to jointly develop a platform that uses AI in a targeted manner for specific industries, such as healthcare and robotics. In view of the AI boom, it is becoming increasingly compelling to explore second- and third-tier stocks that could benefit from the surge in innovation and investor interest.
Read
Commented by Stefan Feulner on October 7th, 2025 | 07:35 CEST
AMD, NetraMark, Adobe – AI latecomers with significant catch-up potential
The market is currently hotly debating when the AI bubble will finally burst. Investors are becoming increasingly nervous, as the valuations of many companies, such as Palantir and Nvidia, are at levels seen just before the dot-com bubble in the early 2000s. However, not all companies related to artificial intelligence are overvalued. Especially in niche segments, there are still hidden gems to be found that have the potential to multiply in value.
Read